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Treatment with vitamin K antagonists (VKA) requires a high proportion of time in the thera-
peutic range (TTR) and a low international normalised ratio (INR) variability to be maximally
safe and effective. Switching from short-acting acenocoumarol to long-acting phenprocou-
mon could improve VKA control.
Aims
We assessed whether switching from acenocoumarol to phenprocoumon improves the time
in the therapeutic range (TTR) and INR variability.
Methods and results
In a retrospective cohort with data on 236,957 patients-years of VKA management from two
first-line anticoagulation clinics in the Netherlands, we identified 124 patients in target range 2–3,
269 patients in target range 2–3.5 and 98 patients in target range 2.5–3.5 who switched from
acenocoumarol to phenprocoumon. They were matched in a 1:2 ratio to non-switching controls
using propensity score matching. Over the first 180 days after a switch, switchers’ TTR declined
5 (95% CI 1 to 10), 10 (95% CI 7 to 13) and 5 (95% CI 0 to 11) percentage points relative to non-
switchers, in target ranges 2–3, 2–3.5 and 2.5–3.5. Anticoagulation was more often supra-thera-
peutic in switchers, and switchers had a higher INR variability. In the following 180 days, TTR in
switchers became 1 (95% CI -4 to 6), 4 (95% CI 0 to 7) and 6 (95% CI 1 to 12) percentage points
better than in non-switchers. Switchers’ INRs were much more stable than non-switchers’.
Conclusion
Eventually, a switch from acenocoumarol to phenprocoumon leads to a higher TTR and a
lower INR variability. However, this is preceded by a transition period with opposite effects.
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An improved conversion algorithm could possibly shorten the transition period. Until then,
physicians and patients should decide whether switching is worth the increased risk during
the transition phase.
Introduction
Vitamin K antagonists (VKAs) are prescribed to treat and prevent thrombosis in venous
thromboembolism, atrial fibrillation, heart valve replacement, and some other indications.
Their effect is unpredictable and requires frequent monitoring to obtain an anticoagulation
intensity (international normalised ratio (INR)) within the therapeutic range. Treatment is saf-
est and most effective when the time within the therapeutic range (TTR) is high [1,2] and the
INR variability is low [3]. Unfortunately, despite frequent monitoring, not all patients achieve
this.
With the introduction of the direct oral anticoagulants (DOACs), the treatment arsenal
expanded. Many patients have switched from a VKA to a DOAC. However, DOACs are con-
traindicated in mechanical heart valves, renal insufficiency, and in combination with certain
interacting drugs. Furthermore, because a poor TTR can be the result of poor medication
adherence, physicians may be reluctant to switch such patients to a DOAC. Therefore, inter-
ventions to optimise VKA treatment remain relevant.
A possible intervention is to switch to a vitamin K antagonist with a longer half-life. Theo-
retically, a longer-acting drug would be less sensitive to suboptimal medication adherence and
produce more stable INRs. In the Netherlands, only short-acting acenocoumarol (half-life
8–11 hours) and long-acting phenprocoumon (half-life 160 hours) are available. Data on the
effect of switching from acenocoumarol to phenprocoumon on TTR are lacking completely;
studies with other VKAs ignore natural variation in TTR. We aimed to determine whether
switching from acenocoumarol to phenprocoumon increased TTR and decreased INR vari-
ability in practice.
Methods
This is a retrospective cohort study with patients from two first-line thrombosis services in the
Netherlands. Of patients who switched to phenprocoumon, we compared TTR and INR vari-
ability before and after the switch. We also assessed whether this change differed from that in
matched non-switchers, to account for the natural evolution of TTR and INR variability over
time. We hypothesised that the switch to phenprocoumon would increase TTR and decrease
INR variability.
Data sources and patient selection
In the Netherlands, VKA management is delegated to dedicated first-line regional “Thrombo-
sis Services” that organise INR checks and adjust the VKA dose. Each thrombosis service uses
one preferred VKA. Certe Trombosedienst and Trombosedienst Maastricht UMC+ are two
thrombosis services, in the north and south of the Netherlands, respectively, that routinely use
acenocoumarol. Thrombosis Service physicians can suggest switching a patient to phenpro-
coumon; the treating physicians usually follow this suggestion.
We extracted INR and VKA dosing records of adult patients who used acenocoumarol or
switched from acenocoumarol to phenprocoumon, in target ranges 2–3, 2.5–3.5 or 2–3.5 (used
for low-intensity anticoagulation before switching to the internationally recommended target
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range of 2–3 on January 1st, 2016), indicated for atrial fibrillation (AF), venous thromboembo-
lism (VTE) or mechanical heart valve replacement (MVR). Data were extracted on July 17th,
2018 (Certe Trombosedienst) and June 20th, 2019 (Trombosedienst Maastricht UMC+). We
excluded the first 90 days of treatment with vitamin K antagonists because INRs are unstable
in the initiation period.
All data were anonymised before they were provided to the researchers. The Medical Ethics
Review Board of the University of Groningen confirmed that this study required no ethical
approval.
Switchers. We selected patients who used acenocoumarol for at least 180 days (excluding
the initial 90 days) before switching to phenprocoumon, and had follow-up INR measure-
ments for at least a further 180 days. The study size was based on the number of patients who
switched.
Non-switchers. Non-switchers were defined as patients who used acenocoumarol during
their entire treatment course or up to date of data extraction. For every calendar date on which
a switcher switched, we selected patients who used acenocoumarol for the previous 180 days
(excluding the initial 90 days) and next 180 days, with the same target range. At this stage, one
non-switcher could be selected to be a control for multiple switch dates, if their follow-up was
long enough. We then later randomly selected one instance per patient, to prevent over-repre-
sentation of long-term non-switchers in the matching strategies.
Subgroups. We defined subgroups of special interest, based on the prompt for switching
and special clinical considerations. A switch could be prompted by a low acenocoumarol dose
requirement, a suboptimal TTR or high variability. We separately analysed patients who used
less than 1.5mg acenocoumarol per day, patients who had a TTR <60% and patients with a
baseline INR variability above the 75th percentile in their target range. In addition, we provide
specific information about patients with a mechanical heart valve (who are confined to VKA),
and the elderly (aged�70 years; who are more likely to have contraindications to restrict other
forms of anticoagulation).
Outcomes
We calculated the proportion of time in the therapeutic range (TTR) as well as the time below
and above the range for each patient using linear interpolation according to the Rosendaal
method [4]. Additionally, TTR was dichotomised with a cut-off of 65% because patients with a
TTR� 65% have a favourable risk profile for bleeding and thrombosis [1]. INR variability was
calculated using Fihn’s method [5] (equation). Furthermore, we determined the mean INR












We distinguished three periods: the 180 days before a patient’s switch to phenprocoumon,
the 180 days after switch, and a period from 180 to 360 days (see Fig 1). For non-switchers, we
used the switch date from the corresponding switcher. All differences were calculated with the
180 days before the switch (baseline) as reference. Because the distribution of the INR variabil-
ity is skewed, the difference of the log-transformed INR variability was used (which is equiva-
lent to the log-transformed ratio of INR variabilities). The VKA dose is reported as the mean
dose during a certain period, and as a percentage of a patient’s mean dose during the 180 days
before the switch.
PLOS ONE Effect of switching from acenocoumarol to phenprocoumon on quality of anticoagulation treatment
PLOS ONE | https://doi.org/10.1371/journal.pone.0235639 July 10, 2020 3 / 17
Statistical analyses
Switchers over time. For the initial analysis, we summarised the TTR and INR variability
as median and interquartile range. Differences were tested using a one-sample Wilcoxon rank-
sum test. Intra-individual correlations were summarised using the Spearman correlation.
Switchers compared with non-switchers. We compared the differences in VKA quality
parameters between switchers and non-switchers, to isolate the effect of the switch to phenpro-
coumon. Non-switchers were matched to switchers in a 2:1 ratio using propensity scores
based on age, sex, indication for VKA therapy, duration of VKA therapy until (virtual) switch,
the mean acenocoumarol dose in the six months before (virtual) switch, the times below and
above range and the log-transformed INR variability. The propensity score was determined by
logistic regression, and matching was performed using the MatchIt package [6] in R version
3.6.1 (2019-07-05) (R core team, Vienna, Austria). This matching procedure was repeated for
every group of special interest.
Differences from baseline were analysed using a mixed linear effects model [7] to account
for non-independence within matched sets. The time between INR measurements was com-
pared in the later periods independent from the time between INR measurements during base-
line, to prevent distortion by any extra monitoring before the anticipated switch. The time
between INR measurements was log-transformed to approach normality. We calculated the
difference in probability to obtain a good TTR (� 65%) between switchers and matched non-
switchers based on the observed frequencies.
Reporting. Values are reported as mean ± SD or median [interquartile range], as appro-
priate. A p-value below 5% was considered significant for all analyses; estimates are given as
point estimate (95% confidence interval).
Results
Patient selection
Patient selection is outlined in Fig 2.
The thrombosis service Groningen contributed 28,756 eligible patients from September 25,
1991, onwards, with a total follow-up of 207,963 patient-years. The thrombosis service
Fig 1. Periods distinguished in the analyses. Solid lines indicate the time period used in the analyses. A period in which acenocoumarol was used, is shown in
black; phenprocoumon is shown in red.
https://doi.org/10.1371/journal.pone.0235639.g001
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Fig 2. Flowchart of patient selection in this study.
https://doi.org/10.1371/journal.pone.0235639.g002
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Maastricht contributed 3,645 patients from January 02, 1997, onwards, with 28,994 patient-
years of follow-up.
There were relatively more switchers in Maastricht than in Groningen. Although Maas-
tricht contributed only 11% of patients, they contributed 47% of switchers (234, versus 264 in
Groningen). Four hundred and ninety-one switchers could be matched to 982 controls.
Patient characteristics
Characteristics of switchers are summarised in Table 1; characteristics of all potential controls,
and subgroups of switchers, are shown in the Supplementary Material.
Switchers achieved a lower TTR and their INRs were more volatile in the period before they
switched than unmatched non-switchers.
The daily acenocoumarol dose differed between cases and controls as well: switchers from
Maastricht, where a low dose requirement is a trigger to consider switching, indeed required a
lower dose than unmatched non-switchers. In Groningen, where no such trigger is formally
defined, switchers generally use a higher dose than the other patients in the anticoagulation
clinic.
Men are less likely to be switched across all target ranges, yet they still outnumber women
in target range 2.5–3.5, as they are more prone to cardiac indications for anticoagulation.
Switching: Dosing and monitoring
Patients who switched from acenocoumarol to phenprocoumon were given a lower VKA dose
in milligrams. For target range 2–3, the phenprocoumon dose was lowered to 91 [78–101]% of
the acenocoumarol dose (in mg) in the first 180 days. In the other target ranges, the conversion
factors were lower: 86 [75–97]% for target range 2–3.5 and 88 [73–96]% for target range 2.5–
3.5.
Patients in target ranges 2.0–3.5 and 2.5–3.5 were monitored more often than before their
switch; this was not observed in patients in target range 2.0–3.0 (Table 2). Patients who
Table 1. Characteristics of patients included in the study.
Target range 2.0–3.0 2.0–3.5 2.5–3.5
N 124 273 101
Center Groningen 30 166 68
Center Maastricht 94 107 33
Age (median [IQR]) 80 [68, 85] 73 [62, 80] 65 [56, 74]
Male gender (%) 56 (45.2) 123 (45.1) 55 (54.5)
VKA experience (median [IQR]) 5 [3, 11] 2 [1, 5] 6 [2, 12]
Dose (median [IQR]) 1.1 [0.9, 2.8] 2.7 [1.5, 4.3] 3.1 [1.8, 4.3]
Acenocoumarol dose <1.5mg (%) 75 (60.5) 68 (25.3) 21 (21.4)
Below range (median [IQR]) 23.8 [15.5, 37.7] 13.8 [4.4, 27.6] 28.7 [10.5, 49.2]
TTR (median [IQR]) 45.3 [33.6, 53.7] 64.1 [47.0, 79.0] 36.5 [21.5, 47.5]
Above range (median [IQR]) 27.9 [15.7, 40.5] 14.4 [2.2, 29.8] 32.0 [13.3, 46.4]
TTR <60% (%) 106 (85.5) 119 (43.6) 89 (88.1)
Mean INR (median [IQR]) 2.7 [2.3, 2.9] 2.8 [2.4, 3.2] 3.2 [2.6, 3.6]
INR variability (median [IQR]) 0.52 [0.32, 0.80] 0.40 [0.23, 0.67] 0.50 [0.31, 0.91]
Mean number of days between INRs (median [IQR]) 11.7 [9.6, 14.6] 14.0 [10.7, 17.6] 11.9 [9.2, 14.6]
Atrial fibrillation (%) 96 (77.4) 223 (81.7) 43 (42.6)
Venous thromboembolism (%) 27 (21.8) 52 (19.0) 12 (11.9)
Mechanical heart valve (%) 6 (4.8) 5 (1.8) 64 (63.4)
https://doi.org/10.1371/journal.pone.0235639.t001
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required more INR measurements before their switch, were checked more often after their
switch (Spearman ρ 0.35 (95% CI 0.19 to 0.50), 0.46 (95% CI 0.36 to 0.55) and 0.54 (95% CI
0.38 to 0.66) for target ranges 2.0–3.0, 2.0–3.5 and 2.5–3.5).
After the first 180 days, the phenprocoumon dose was lowered further, to 85 [71–99]% of
the baseline acenocoumarol dose in target range 2–3, 78 [67–92]% in target range 2–3.5 and 79
[66–94]% in target range 2.5–3.5.
Monitoring intervals were prolonged across all target ranges (Table 2). For target range
2–3, the monitoring interval was no longer related to the monitoring interval at baseline (ρ
0.08 (95% CI -0.11 to 0.25)).
Effect of switching
The evolution of VKA quality parameters after switching from acenocoumarol to phenprocou-
mon is summarised in Table 2A–2C. Patients in target range 2–3 showed a marked immediate
improvement in TTR. This was not true for patients in the other target ranges, where the
Table 2. A. VKA quality parameters in patients in target range 2.0–3.0 who switched from acenocoumarol to
phenprocoumon. B. VKA quality parameters in patients in target range 2.0–3.5 who switched from acenocoumarol to
phenprocoumon. C. VKA quality parameters in patients in target range 2.5–3.5 who switched from acenocoumarol to
phenprocoumon.
Before switch Short-term Long-term
A
TTR 45% [34–54] 51% [37–64], p = 0.001 62% [43–75], p = <0.001
above range 28% [16–40] 24% [12–39], p = 0.589 17% [0–36], p = 0.045
below range 24% [15–38] 18% [9–33], p = 0.011 11% [0–27], p = <0.001
INR variability 0.52 [0.32–0.80] 0.28 [0.19–0.44], p = <0.001 0.17 [0.12–0.26], p = <0.001
mean INR 2.7 [2.3–2.9] 2.6 [2.3–3.0], p = 0.773 2.5 [2.3–2.9], p = 0.385
dose 1.1 [0.9–2.8] 1.1 [0.8–2.3], p = <0.001 1.1 [0.8–2.2], p = <0.001
dose ratio ref 91% [78–101], p = <0.001 85% [70–99], p = <0.001
mean number of days between INRs 12 [10–15] 11 [10–14], p = 0.401 17 [13–20], p = <0.001
B
TTR 64% [47–79] 62% [48–73], p = 0.173 77% [60–92], p = <0.001
above range 14% [2–30] 25% [16–38], p = <0.001 15% [0–26], p = 0.850
below range 14% [5–28] 7% [2–17], p = <0.001 0% [0–12], p = <0.001
INR variability 0.40 [0.23–0.67] 0.32 [0.22–0.50], p = <0.001 0.18 [0.12–0.32], p = <0.001
mean INR 2.8 [2.4–3.2] 3.0 [2.7–3.4], p = <0.001 3.0 [2.7–3.2], p = <0.001
dose 2.7 [1.5–4.3] 2.3 [1.5–3.3], p = <0.001 2.0 [1.2–3.1], p = <0.001
dose ratio ref 86% [75–97], p = <0.001 78% [67–92], p = <0.001
mean number of days between INRs 14 [11–18] 12 [10–15], p = <0.001 19 [14–27], p = <0.001
C
TTR 36% [22–47] 36% [24–51], p = 0.684 49% [34–66], p = <0.001
above range 32% [13–47] 38% [22–56], p = 0.003 30% [7–43], p = 0.774
below range 28% [10–49] 12% [5–34], p = <0.001 10% [0–27], p = <0.001
INR variability 0.50 [0.31–0.93] 0.45 [0.31–0.61], p = 0.037 0.22 [0.14–0.43], p = <0.001
mean INR 3.2 [2.7–3.6] 3.3 [2.9–3.8], p = 0.012 3.2 [2.9–3.5], p = 0.804
dose 3.1 [1.8–4.3] 2.4 [1.6–3.5], p = <0.001 2.2 [1.6–3.2], p = <0.001
dose ratio ref 88% [73–96], p = <0.001 79% [66–93], p = <0.001
mean number of days between INRs 12 [9–15] 11 [9–13], p = 0.013 16 [12–20], p = <0.001
P-values from Wilcoxon rank-sum test.
https://doi.org/10.1371/journal.pone.0235639.t002
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improvements were only seen in the long-term period (180 to 360 days after the switch). In
these target ranges, the time above the target range increased at the expense of not only the
time below the range, but also the time in the therapeutic range. INR variability decreased
across all target ranges.
The TTR achieved after the switch was only weakly related to the TTR before the switch:
Spearman ρ was 0.26 (95% CI 0.09 to 0.42) for target range 2.0–3.0, 0.22 (95% CI 0.10 to 0.33)
for target range 2.0–3.5 and 0.05 (95% CI -0.15 to 0.24) for target range 2.5–3.5. In target range
2.5–3.5 there was a moderate positive association between the time above the range at baseline
and after the switch (ρ 0.43 (95% CI 0.26 to 0.58)), that persisted in the later period (ρ 0.45
(95% CI 0.27 to 0.59)). The same was found for the time below the range (ρ 0.41 (95% CI 0.24
to 0.56) and 0.37 (95% CI 0.19 to 0.53)). In other target ranges, this effect was not observed.
Comparison with non-switchers
Four hundred and ninety-one switchers could be matched with 982 non-switching controls,
with a high similarity between the two groups (standardised mean difference in propensity
scores was 0.08 for target range 2–3; 0.02 for target range 2–3.5 and 0.07 for target range 2.5–
3.5). The coefficients from the propensity score matching and the patient characteristics from
matched patients are shown in S3 and S4 Tables, respectively. The difference in outcomes
between switchers and matched non-switchers is shown in Table 3A–3C and Figs 3–5.
When comparing switchers with non-switchers, the initial effect of switching is negative:
TTR decreases mainly owing to an increase in the time above the range. At the same time, the
INR variability increases, though only statistically significantly in target range 2–3.5. In the
first six months, switchers are less likely to obtain or maintain a TTR�65%: the absolute risk
difference was -13 (95% CI -22 to -3) percentage points for target range 2.0–3.0; for target
range 2.0–3.5 it was -20 (95% CI -27 to -12); for target range 2.5–3.5 the risk difference was -5
Table 3. A. Difference in changes since baseline of switchers versus matched non-switching controls in target
range 2.0–3.0, with 95% confidence interval. B. Difference in changes since baseline of switchers versus matched
non-switching controls in target range 2.0–3.5, with 95% confidence interval. C. Difference in changes since baseline
of switchers versus matched non-switching controls in target range 2.5–3.5, with 95% confidence interval.
Short-term difference Long-term difference
A
TTR -5.5pp (-9.6 to -1.3), p = 0.01 0.8pp (-4.4 to 6.1), p = 0.76
above range 5.8pp (0.8 to 10.8), p = 0.02 0.8pp (-4.9 to 6.4), p = 0.79
below range -0.3pp (-4.9 to 4.3), p = 0.90 -1.8pp (-6.8 to 3.2), p = 0.49
INR variability� 0.03 (-0.18 to 0.24), p = 0.75 -0.34 (-0.57 to -0.12), p = 0.00
B
TTR -9.8pp (-12.9 to -6.7), p = 0.00 3.9pp (0.4 to 7.4), p = 0.03
above range 12.3pp (9.2 to 15.4), p = 0.00 1.7pp (-1.3 to 4.7), p = 0.26
below range -2.5pp (-4.9 to 0.0), p = 0.05 -5.6pp (-8.4 to -2.8), p = 0.00
INR variability� 0.08 (-0.06 to 0.23), p = 0.26 -0.35 (-0.50 to -0.21), p = 0.00
C
TTR -5.4pp (-10.8 to 0.0), p = 0.05 6.4pp (0.8 to 12.1), p = 0.03
above range 6.2pp (0.2 to 12.3), p = 0.04 -1.3pp (-7.6 to 4.9), p = 0.68
below range -0.8pp (-6.3 to 4.6), p = 0.77 -5.1pp (-10.6 to 0.4), p = 0.07
INR variability� 0.14 (-0.06 to 0.34), p = 0.17 -0.55 (-0.76 to -0.34), p = 0.00
An asterisk indicates that values were log-transformed in the analyses.
P-values from a linear mixed model.
https://doi.org/10.1371/journal.pone.0235639.t003
PLOS ONE Effect of switching from acenocoumarol to phenprocoumon on quality of anticoagulation treatment
PLOS ONE | https://doi.org/10.1371/journal.pone.0235639 July 10, 2020 8 / 17
(95% CI -12 to 3). Switchers’ INRs were monitored more often, with 24% (95% CI 18 to 29)
less time between INR measurements for target range 2–3; 22% (95% CI 18 to 25) for target
range 2–3.5 and 29% (95% CI 23 to 35) for target range 2.5–3.5.
Positive effects occur in the second six-month period after switching. TTR mildly increases,
with 0.8 (95% CI -4.4 to 6.1), 3.9 (95% CI 0.4 to 7.4) and 6.4 (95% CI 0.8 to 12.1) percentage
points in target ranges 2.0–3.0, 2.0–3.5 and 2.5–3.5, respectively. The INR variability strongly
decreases across all target ranges. During this period, switchers in target ranges 2–3 and 2–3.5
were slightly more likely to obtain a TTR�65%: absolute risk differences were 2 (95% CI -9 to
13) and 6 (95% CI -1 to 13). The effect was more pronounced in target range 2.5–3.5, where
patients were 15 (95% CI 6 to 25) percentage points more likely to obtain a TTR�65%.
Switchers in target ranges 2–3 and 2.5–3.5 were no longer monitored more often than their
matched non-switching controls (they had 2% (95% CI -6 to 12) and 2% (95% CI -6 to 12)
more time between measurements). Patients in target range 2–3.5 had 14% (95% CI 8 to 22)
more time between INR measurements.
Effect in subgroups. We compared the effect of a switch in several groups of special inter-
est. Patient characteristics of switchers in these groups, and their matched non-switchers, are
summarised in S4 Table. Again, matching was successful: standardised mean differences in
Fig 3. Proportion of time spent in, above or below the target range of 2.0–3.0, and INR variability, in switchers and matched non-switchers. Median and
interquartile range.
https://doi.org/10.1371/journal.pone.0235639.g003
Fig 4. Proportion of time spent in, above or below the target range of 2.0–3.5, and INR variability, in switchers and matched non-switchers. Median and
interquartile range.
https://doi.org/10.1371/journal.pone.0235639.g004
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propensity scores were<0.1 in all subgroups, except in some subgroups in target range 2.5–
3.5: patients with high INR variability (standardised mean difference (SMD) in propensity
scores 0.13), elderly patients (SMD 0.20), and patients with mechanical heart valves (SMD
0.12).
The effect of a switch relative to non-switchers is summarised in S5 Table and shown in
Figs 6–8.
Fig 6. Changes in time in the therapeutic range (TTR) of 2.0–3.0 and international normalised ratio (INR) variability in patients who switched from
acenocoumarol to phenprocoumon, relative to matched non-switchers. The grey area indicates the 95% confidence interval of the difference in the overall analysis.
https://doi.org/10.1371/journal.pone.0235639.g006
Fig 5. Proportion of time spent in, above or below the target range of 2.5–3.5, and INR variability, in switchers and matched non-switchers. Median and
interquartile range.
https://doi.org/10.1371/journal.pone.0235639.g005
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The effect of a switch on TTR was consistent in groups with different prompts for switching
(a low dose, a poor TTR or a high INR variability). In target ranges 2–3 and 2–3.5, patients
with a poor TTR and patients with high INR variability who switched were initially relatively
over-anticoagulated compared with patients with a low VKA dose before their switch. This dif-
ference disappeared after the first 180 days. In target range 2–3.5, the INRs of patients whose
switch was prompted by a low VKA dose stabilised quicker than the INRs of patients with a
poor TTR.
We also evaluated the effect of a switch in patients who require specific clinical consider-
ation: i.e. the elderly and patients with a mechanical heart valve. Initially, the effect of a switch
on TTR in these groups is comparable to the effect in the whole population. In the long term,
however, the TTR of elderly patients in target ranges 2–3.5 and 2.5–3.5 seems not to improve
by switching, nor does the TTR of patients with a mechanical heart valve and target range 2.5–
3.5.
Discussion
In this study, we analysed the effect of switching from acenocoumarol to phenprocoumon on
the achieved quality of anticoagulation in patients from two Dutch anticoagulation clinics. We
found that patients’ time in the therapeutic range and INR variability do not improve in the
first six months, compared with non-switching matched controls. In the second six-month
period after a switch, however, INR variability decreases and TTR improves.
Fig 7. Changes in time in the therapeutic range (TTR) of 2.0–3.5 and international normalised ratio (INR) variability in patients who switched from
acenocoumarol to phenprocoumon, relative to matched non-switchers. The grey area indicates the 95% confidence interval of the difference in the overall analysis.
https://doi.org/10.1371/journal.pone.0235639.g007
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Although the question which vitamin K antagonist to prefer is far from new, we are the first
to observe the real-life effect of switching from acenocoumarol to phenprocoumon using
matched non-switchers. Previous research only compared groups of patients using different
VKA. Already in the 1960s and early 1970s phenprocoumon showed favourable properties
compared with warfarin [8] and acenocoumarol [9,10] on then-used monitoring parameters.
After the development of the international normalised ratio (INR) to monitor VKA, several
additional studies have been performed, with mixed results. The proportion of INR measure-
ments in range was higher on warfarin than on acenocoumarol in an Italian retrospective
cohort study [11], but not in one from Bosnia and Herzegovina [12]. Two retrospective studies
from the Netherlands found a higher TTR in patients on phenprocoumon, compared with ace-
nocoumarol [5,13]. In clinical practice, anticoagulation clinics in the Netherlands report
higher TTRs in patients on phenprocoumon than patients on acenocoumarol [14]. A retro-
spective study focussing on self-managed patients found a higher TTR on phenprocoumon
than on warfarin [15]. A French randomised controlled trial showed no difference in TTR
between patients initiated with warfarin versus those with acenocoumarol, but INR variability
was lower in the warfarin group [16]. This implies that phenprocoumon (with the longest half-
life) might lead to a higher TTR than warfarin (with the intermediate half-life); warfarin, in
turn, could cause a higher or similar TTR to acenocoumarol (with the shortest half-life). How-
ever, these studies did not assess the effect of switching from one VKA to another on the qual-
ity of anticoagulation.
Fig 8. Changes in time in the therapeutic range (TTR) of 2.5–3.5 and international normalised ratio (INR) variability in patients who switched from
acenocoumarol to phenprocoumon, relative to matched non-switchers. The grey area indicates the 95% confidence interval of the difference in the overall analysis.
https://doi.org/10.1371/journal.pone.0235639.g008
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Two studies describe the switch from acenocoumarol to warfarin. An Italian group found
no increase in the number of prothrombin times in range [17]. The results of this study are dif-
ficult to generalise because the group of patients had heterogeneous indications for anticoagu-
lation and it is unclear how these patients were selected. A Polish study, confined to younger
patients with arbitrarily defined “unstable anticoagulation”, found a marked increase in TTR
after the switch [18]. Because both studies lacked a control group, and TTR is not stable over
time [19], their results could be distorted by “regression” to the mean.
In our study, we separated the switching effect from the natural course of anticoagulation
therapy and bias by indication with the use of matched non-switching controls. However,
matching is sensitive to unmeasured confounders. We have included almost all the limited
data available to anticoagulation clinics in the matching, and we believe they included the
most relevant confounders. However, we could not control for a switch due to the start of
interacting medication (e.g. rifampicin).
We could not assess the effect of a switch on the incidence of bleeding and thrombotic
events, because we lacked the data. Instead, we measured TTR and INR variability. TTR and
INR variability link the joint pharmacological effect of all vitamin K antagonists to bleeding
and thrombotic complications [1–3]. Additional mechanisms leading to bleeding or thrombo-
sis, specific to one vitamin K antagonist, are unknown and implausible. Therefore, TTR and
INR variability are accepted proxy measures.
The observational nature of our study only allowed us to analyse patients who actually
switched. Strictly speaking, our study cannot be generalised to patients whose physicians do
not see an indication to switch. However, our results are similar to those from earlier studies
comparing patients on the two drugs without switching [5,13]. Nevertheless, the TTR
improvement in our study seems smaller than the TTR difference observed between anticoa-
gulation clinics using primarily phenprocoumon instead of acenocoumarol [14]. We have
insufficient data to assess whether this effect persists after adjustment for differences in case-
mix. Another explanation would be a difference in experience with managing
phenprocoumon.
Other strong points of our study are the real-life setting and the analysis in contemporary
target ranges; previously, higher intensity anticoagulation therapy was prescribed. Our find-
ings are more robust because they stem from two independent thrombosis services.
The eventual increase in TTR and decrease in INR variability after switching to phenpro-
coumon are intuitive; factor VII levels fluctuate more during the day under acenocoumarol
than under phenprocoumon [20,21]. This effect could be more prominent in higher target
ranges, where small variances in coagulation factors result in higher changes in the INR than
in lower target ranges [22]. However, it is unknown whether the increased stability of factor
VII levels on phenprocoumon also extends over periods of weeks instead of a single day. Fur-
thermore, this cannot explain why the beneficial effect is only seen after a “transition period”.
The transition period following a switch is characterised by unfavourable effects on VKA
control: a decreased TTR and a higher INR variability. Patients are more prone to bleeding,
owing to a higher proportion of time above the target range [2]. A possible cause is the trial-
and-error during the determination of the optimal individual phenprocoumon dose. In gen-
eral, the anticoagulation clinics follow the Dutch guideline, which prescribes a conversion fac-
tor of 84% [23]. However, the resulting over-anticoagulation and the later dose reductions
suggest that this factor, identified in stable patients in higher target ranges [24], might not be
applicable anymore.
In the long run, switching from acenocoumarol to phenprocoumon leads to improved
VKA control. In all target ranges, the switch to phenprocoumon significantly decreases INR
variability. A lower INR variability reduces the risk of bleeding and thrombosis [25–29], but to
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what extent is difficult to quantify since different authors use different methods to calculate
INR variability. There is no consensus about risk categories based on absolute values of INR
variability, and it remains unclear whether INR variability should be interpreted similarly in
different target ranges.
A switch to phenprocoumon also significantly improves TTR in target ranges 2–3.5 and
2.5–3.5, relative to non-switching controls. The TTR improvement is most pronounced in tar-
get range 2.5–3.5, with a difference of 6.4 (95% CI 0.8 to 12.1) percentage points. The associ-
ated clinical benefit cannot be quantified exactly because the relationship between TTR and
incidence of events is not linear [2]. Patients with a TTR� 65% have substantially reduced
risks of bleeding, thrombosis and death, compared with patients with a TTR < 65% [1]. One
additional patient out of every 6.5 (95% CI 4.0–18.1) patients in target range 2.5–3.5 who
switch, attains a TTR in this favourable risk category. TTR differences were smaller in target
ranges 2–3 and 2–3.5, and more patients need to switch to cause an additional TTR� 65%:
48.0 (95% CI NNT 7.7 to1 to NNH 11.3) and 16.9 (95% CI NNT 7.7 to1 to NNH 84.5),
respectively. One could argue that the effect of moving from a TTR < 65% to a TTR� 65%
with a small TTR difference is trivial, because the differences in these categories will be driven
by a larger TTR variation.
The benefit of an improved TTR does not extend to patients with a mechanical heart valve
prosthesis, nor to elderly patients in target range 2–3.5 or 2.5–3.5 (the latter even seem to
decline). Although the findings in this group are less robust, owing to the smaller sample size
and less perfect matching, they are cause for concern. The efficacy and safety of VKA are para-
mount in these groups because alternative forms of anticoagulation might be contraindicated.
Fortunately, elderly patients in target range 2–3 do increase in TTR after the switch. Elderly
patients across the target ranges, and patients with mechanical heart valves, obtain a lower
INR variability. However, it is questionable whether the decreased INR variability cancels out
the neutral or unfavourable effect on TTR, the risks associated with the transition period, and
the risk of medication errors with drugs that are less commonly used.
Conclusion
Eventually, the switch from acenocoumarol to phenprocoumon improves the time in the ther-
apeutic range and decreases the INR variability. However, this is preceded by a transition
period, where TTR is lower and mostly the time above the range is increased. Physicians and
their patients should weigh the benefit of a small improvement in VKA control and the risk of
the transition period.
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